Pharma Focus Europe

AmplifyBio and Xcell Biosciences Collaborate on Manufacturing Solid Tumor-Targeting TCR-T Cell Therapy

Tuesday, May 21, 2024

Xcell Biosciences Inc. (Xcellbio) and AmplifyBio have announced a collaborative initiative to enhance the manufacturing process for engineered T-cell receptor (TCR) therapies targeting solid tumors. Their preliminary findings will be presented at the annual meeting of the International Society for Cell & Gene Therapy (ISCT 2024) in Vancouver, British Columbia, from May 29 to June 1.

AmplifyBio, stressed the importance of improving therapies for solid tumors and expressed confidence in the partnership with Xcellbio and their AVATAR Foundry platform to achieve this goal. Ganjei emphasized the urgent need for more potent therapies, highlighting the potential impact of the collaboration's results on patient care.

Xcellbio, discussed the challenges associated with treating solid tumors and the potential of the AVATAR Foundry platform to address these challenges. Lim emphasized the platform's ability to improve the manufacturability and efficacy of engineered TCRs, offering scalable and cost-effective solutions.

The joint effort will leverage Xcellbio's AVATAR Foundry platform, known for its innovative capabilities in cell therapy manufacturing, to develop improved manufacturing methods for TCR therapies. The focus will be on optimizing key factors such as product characterization, metabolic profiles, and potency. An IND filing is expected next year for a therapy targeting human papillomavirus-positive (HPV+) tumors using engineered TCRs.

Xcellbio, expressed excitement about the collaboration with AmplifyBio, citing their expertise in supporting therapy development. Feth highlighted the potential of T cells cultivated in the AVATAR system to exhibit enhanced potency and tumor-killing activity, offering promise for future patient care.

At ISCT 2024, scientists from both companies will present a joint poster titled "Adapting T Cells for the Tumor Microenvironment (TME) During Manufacturing for Improved Anti-Tumor Potency," showcasing data on metabolically conditioned T cells in the AVATAR system.

 

Source: businesswire.com

magazine-slider-img
Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024
cytiva